Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Adds recruitment-status notice and new user guidance sections, and updates the Intervention/Treatment label and revision version, while removing the older revision label.
    Difference
    0.1%
    Check dated 2026-06-13T17:50:30.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a minor update to the page template.
    Difference
    0.0%
    Check dated 2026-06-06T14:19:10.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.5.3 to v3.5.4, and the old AstraZeneca study locator contact block was removed.
    Difference
    0.0%
    Check dated 2026-05-15T23:59:17.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    The page’s footer has updated the ClinicalTrials.gov interface revision/version from v3.5.2 to v3.5.3. This reflects a platform update rather than a change to the displayed study details.
    Difference
    0.0%
    Check dated 2026-04-24T16:52:39.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T13:43:35.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Napoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the study locations.
    Difference
    0.0%
    Check dated 2026-03-27T02:14:43.000Z thumbnail image

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.